Skip to main content
Signal8

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

$ZURAPress releaseJun 29, 2026, 7:30 AM ETRead the release

Zura Bio announced that it has exceeded enrollment targets in two Phase 2 trials for tibulizumab, TibuSHIELD in hidradenitis suppurativa and TibuSURE in systemic sclerosis, enrolling 247 and over 80 participants respectively. The company plans to initiate a Phase 2 study in a third indication by year-end 2026, with topline data from the current trials expected in Q4 2026 and H1 2027.

Key figures

Drug Name
tibulizumab
Phase Of Trial
Phase 2
Cash balance
$225.6 million
Tibusure enrollment
80
Tibushield enrollment
247

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ZURA: Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program — AI Analysis | Signal8